|

JSKN003 Clinical Trials

3 actively recruiting trials

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Shanghai JMT-Bio Inc.1
  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd1
  • Fudan University1

Indications

  • Breast Cancer3
  • Cancer3
  • Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants1
  • Hormone Receptor Negative Tumor1
  • Hormone Receptor Positive Tumor1

Other3 trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Phase 3
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.